NDC 67386-130

Vyepti

Eptinezumab-jjmr

Vyepti is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Lundbeck Pharmaceuticals Llc. The primary component is Eptinezumab.

• Product ID: 67386-130_1156608e-bd62-4927-b627-f8a24e8d4170
• NDC: 67386-130
• Product Type: Human Prescription Drug
• Proprietary Name: Vyepti
• Generic Name: Eptinezumab-jjmr
• Dosage Form: Injection
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2020-02-21
• Marketing Category: BLA / BLA
• Application Number: BLA761119
• Labeler Name: Lundbeck Pharmaceuticals LLC
• Substance Name: EPTINEZUMAB
• Active Ingredient Strength: 100 mg/mL
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 67386-130-51

1 VIAL, SINGLE-DOSE in 1 CARTON (67386-130-51) > 1 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2020-02-21
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 67386-130-51 [67386013051]

Vyepti INJECTION

• Marketing Category: BLA
• Application Number: BLA761119
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2020-02-21

Drug Details

Active Ingredients

Ingredient	Strength
EPTINEZUMAB	100 mg/mL

OpenFDA Data

• SPL SET ID: 79065861-6aa5-4d1f-829f-3a6471286b36
• Manufacturer:
  • Lundbeck Pharmaceuticals LLC
• UNII:
  • 8202AY8I7H
• RxNorm Concept Unique ID - RxCUI:
  • 2283054
  • 2283049